Abstract
Ovarian cancer accounts for more deaths than any other gynecologic malignancy. According to the Ovarian Cancer National Alliance, overall mortality rates due to ovarian cancer have not significantly improved in 40 years, a statistic that highlights the need for innovative treatment strategies. Immune checkpoint inhibitors are part of an emerging immunotherapeutic model that seeks to “inhibit the inhibitors” of adequate cancer immunosurveillance. Immune checkpoints encompass a variety of inhibitory pathways that downregulate an immune response, which allows them to assume an important physiologic role in maintaining homeostasis. While cancer cells are adept at utilizing these pathways to their advantage, basic scientists, translational researchers, and clinical trialists are making great strides in this area of investigation. This review article will focus on the development of anti-CTLA-4 and anti-PD1 monoclonal antibodies, their current role in the treatment of advanced stage EOC, and recently published patents that incorporate the use of immune checkpoint inhibition in the treatment of cancer.
Keywords: Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), immune checkpoint, immunoediting, ipilimumab, nivolumab, ovarian cancer, pembrolizumab, programmed cell death protein 1 (PD-1).
Recent Patents on Anti-Cancer Drug Discovery
Title:Immune Checkpoint Inhibition: Therapeutic Implications in Epithelial Ovarian Cancer
Volume: 10 Issue: 2
Author(s): Teresa C. Longoria and Ramez N. Eskander
Affiliation:
Keywords: Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), immune checkpoint, immunoediting, ipilimumab, nivolumab, ovarian cancer, pembrolizumab, programmed cell death protein 1 (PD-1).
Abstract: Ovarian cancer accounts for more deaths than any other gynecologic malignancy. According to the Ovarian Cancer National Alliance, overall mortality rates due to ovarian cancer have not significantly improved in 40 years, a statistic that highlights the need for innovative treatment strategies. Immune checkpoint inhibitors are part of an emerging immunotherapeutic model that seeks to “inhibit the inhibitors” of adequate cancer immunosurveillance. Immune checkpoints encompass a variety of inhibitory pathways that downregulate an immune response, which allows them to assume an important physiologic role in maintaining homeostasis. While cancer cells are adept at utilizing these pathways to their advantage, basic scientists, translational researchers, and clinical trialists are making great strides in this area of investigation. This review article will focus on the development of anti-CTLA-4 and anti-PD1 monoclonal antibodies, their current role in the treatment of advanced stage EOC, and recently published patents that incorporate the use of immune checkpoint inhibition in the treatment of cancer.
Export Options
About this article
Cite this article as:
Longoria C. Teresa and Eskander N. Ramez, Immune Checkpoint Inhibition: Therapeutic Implications in Epithelial Ovarian Cancer, Recent Patents on Anti-Cancer Drug Discovery 2015; 10 (2) . https://dx.doi.org/10.2174/1574892810666150504121000
DOI https://dx.doi.org/10.2174/1574892810666150504121000 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Membrane Transporters as Determinants of the Pharmacology of Platinum Anticancer Drugs
Current Cancer Drug Targets MicroRNA Regulation of TRAIL in Renal Carcinoma: Tiny Juggernauts at Work
Current Molecular Pharmacology TGF-Beta: a Master Switch in Tumor Immunity
Current Pharmaceutical Design Clinical Considerations of Focal Drug Delivery in Cancer Treatment
Current Drug Delivery Nanoemulsion: A Novel Eon in Cancer Chemotherapy
Mini-Reviews in Medicinal Chemistry Folic Acid Conjugated Chitosan Nanoparticles for Tumor Targeting of Therapeutic and Imaging Agents
Pharmaceutical Nanotechnology Targeting the Folate Receptor: Improving Efficacy in Inorganic Medicinal Chemistry
Current Medicinal Chemistry Cancer Immunotherapy: The Role Regulatory T Cells Play and What Can be Done to Overcome their Inhibitory Effects
Current Molecular Medicine Cellular Systems Biology Profiling Applied to Cellular Models of Disease
Combinatorial Chemistry & High Throughput Screening Cyclin-Dependent Kinase Inhibition by Flavoalkaloids
Mini-Reviews in Medicinal Chemistry Regulation and Importance of the PI3K/Akt/mTOR Signaling Pathway in Hematologic Malignancies
Anti-Cancer Agents in Medicinal Chemistry Current Status of Magnetite-Based Core@Shell Structures for Diagnosis and Therapy in Oncology Short running title: Biomedical Applications of Magnetite@Shell Structures
Current Pharmaceutical Design Towards Understanding the Role of Cancer-Associated Inflammation in Chemoresistance
Current Pharmaceutical Design Editorial (Thematic Issue: Antiangiogenic Agents in the Management of Solid Malignancies)
Current Angiogenesis (Discontinued) Progress of HDAC Inhibitor Panobinostat in the Treatment of Cancer
Current Drug Targets Anti-Cancer Potential of a Novel SERM Ormeloxifene
Current Medicinal Chemistry Human Apurinic/Apyrimidinic Endonuclease (APE1): An Emerging Anti-Cancer Biomarker
Recent Patents on Biomarkers Armed Oncolytic Adenoviruses and Polymer-shielded Nanocomplex for Systemic Delivery
Current Cancer Therapy Reviews Chemosensitization and Immunosensitization of Resistant Cancer Cells to Apoptosis and Inhibition of Metastasis by the Specific NF-κB Inhibitor DHMEQ
Current Pharmaceutical Design Current Strategy for Cisplatin Delivery
Current Cancer Drug Targets